<DOC>
	<DOCNO>NCT02599961</DOCNO>
	<brief_summary>UX007G-CL202 open-label , single-arm , multi center extension study ass long-term safety efficacy UX007 Glut 1 DS . The study enroll 40 pediatric , adolescent adult Glut 1 DS subject complete UX007G-CL201 study participate qualified ISTs .</brief_summary>
	<brief_title>Study Assess Long Term Safety Efficacy UX007 Subjects With Glucose Type 1 DS</brief_title>
	<detailed_description>A Phase 2 study ( UX007G-CL-201 ) currently ongoing ass safety efficacy UX007 reduce frequency seizure Glut 1 DS patient . ISTs treatment program also evaluate UX007 treatment Glut 1 DS . This open label long term safety efficacy study ( UX007G-CL202 ) provide opportunity Glut 1 DS patient treat UX007 3 year ( market approval ) single standardize protocol maintenance therapy consistent safety monitoring . The study design obtain long-term safety information evaluate maintenance efficacy pediatric adult Glut 1 DS population .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carbohydrate Metabolism , Inborn Errors</mesh_term>
	<criteria>Diagnosis Glut 1 DS confirm cerebrospinal fluid glucose concentration . erythrocyte 3OmethylDglucose uptake assay , SLC2A1 molecular genetic testing ( Information obtain Medical Records ) Males female age least 1 year old time inform consent Completion UX007GCL201 study ( NCT 01993186 ) . Glut1 DS patient receive UX007/triheptanoin treatment apart clinical study , ISTs expand access/compassionate use treatment program may eligible discretion Sponsor Provide write informed consent verbal assent ( possible ) write informed consent legally authorize representative nature study explain , prior research related procedure Must , opinion investigator , willing able complete aspect study , comply accurate completion seizure diary Females childbearing potential must negative urine pregnancy test Baseline willing additional pregnancy test study . Females consider childbearing potential include experience menarche , postmenopausal ( define mensus least 12 month without alternative medical cause ) , permanently sterile due total hysterectomy , bilateral salpingectomy , bilateral oophorectomy . Participants childbearing potential fertile male partner childbearing potential sexually active must consent use highlyeffective method contraception determine investigator period follow signing informed consent 30 day last dose study drug . Any known hypersensitivity triheptanoin , judgement investigator , place subject increase risk adverse effect History , current suicidal ideation , behavior and/or attempt Pregnant and/or breast feeding infant Unwilling unable discontinue use prohibit medication ( barbiturate , pancreatic lipase inhibitor ) substance may confound study objective . Use 3 concomitant AEDs allow , provide dose stable least 14 day prior Baseline Use Investigational Product , drug supplement ( UX007 ) within 30 day prior Baseline , time study Has condition severity acuity , opinion investigator , warrant immediate surgical intervention treatment Has concurrent disease condition , laboratory abnormality , view investigator , place subject high risk poor treatment compliance complete study , would interfere study participation introduce additional safety concern</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Glut 1 DS</keyword>
</DOC>